Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy.
about
Role of systemic chemotherapy in urothelial urinary bladder cancerTime from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trialsPaclitaxel Carboplatin chemotherapy as a second-line chemotherapy for advanced platinum resistant urothelial cancer in Japanese cases.Methotrexate, vinblastine, doxorubicin and cisplatin combination regimen as salvage chemotherapy for patients with advanced or metastatic transitional cell carcinoma after failure of gemcitabine and cisplatin chemotherapy.Gemcitabine and docetaxel, an effective second-line chemotherapy for lung metastasis of urothelial carcinoma.Phase II trial of combination nab-paclitaxel, carboplatin and gemcitabine in first line therapy of advanced urothelial carcinoma.Combination of docetaxel, ifosfamide and cisplatin (DIP) as a potential salvage chemotherapy for metastatic urothelial carcinoma.Comparison of single agent versus combined chemotherapy in previously treated patients with advanced urothelial carcinoma: a meta-analysis.Systemic therapy in bladder cancerFirst- and second-line therapy for metastatic urothelial carcinoma of the bladderPharmacotherapy of bladder cancer--practice and prospects.Gemcitabine in transitional cell carcinoma of the urothelium.Novel agents for advanced bladder cancer.Controversies in the treatment of invasive urothelial carcinoma: a case report and review of the literature.Successful treatment of metastatic urothelial carcinoma arising in a transplanted renal allograft with paclitaxel, cisplatin, and gemcitabine combination therapy: a case report.Cisplatin-based first-line therapy for advanced urothelial carcinoma after previous perioperative cisplatin-based therapyPredicting the response of patients with advanced urothelial cancer to methotrexate, vinblastine, Adriamycin, and cisplatin (MVAC) after the failure of gemcitabine and platinum (GP).Management of muscle-invasive bladder cancer in the elderly.Use of low-dose combined therapy with gemcitabine and paclitaxel for advanced urothelial cancer patients with resistance to cisplatin-containing therapy: a retrospective analysis.Chemotherapy practices and perspectives in invasive bladder cancer.Front-line Treatment with Gemcitabine, Paclitaxel, and Doxorubicin for Patients With Unresectable or Metastatic Urothelial Cancer and Poor Renal Function: Final Results from a Phase II StudyFrom Clinical Trials to the Front Line: Vinflunine for Treatment of Urothelial Cell Carcinoma at the National Cancer Institute of Naples.Treatment of relapsed urothelial bladder cancer with vinflunine: real-world evidence by the Hellenic Genitourinary Cancer Group.Systemic therapy for metastatic urothelial carcinoma.Current optimal chemotherapy for advanced urothelial cancer.Phase II trial of paclitaxel, carboplatin and gemcitabine in patients with locally advanced carcinoma of the bladder.Efficacy of methotrexate/vinblastine/doxorubicin cisplatin combination in gemcitabine-pretreated patients with advanced urothelial cancer: a retrospective analysis.Critical evaluation of vinflunine in the treatment of refractory metastatic urothelial carcinoma.Role of surgical consolidation in metastatic urothelial carcinomaSystemic therapy of metastatic bladder cancer in the molecular era: current status and future promise.Vinflunine in the treatment of advanced bladder cancer.Current chemotherapeutic strategies against bladder cancer.Second-line systemic therapy for metastatic urothelial carcinoma of the bladder.Chemotherapeutic and targeted biological agents for metastatic bladder cancer: a comprehensive review.Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis.Various Mechanisms Involve the Nuclear Factor (Erythroid-Derived 2)-Like (NRF2) to Achieve Cytoprotection in Long-Term Cisplatin-Treated Urothelial Carcinoma Cell LinesThe safety and efficacy of gemcitabine for the treatment of bladder cancer.Chemotherapy for Muscle-Invasive Bladder Cancer.Improving Systemic Chemotherapy for Bladder Cancer.Metastatic Bladder Cancer: Second-Line Treatment and Recommendations of the Genitourinary Tumor Division of the Galician Oncologic Society (SOG-GU).
P2860
Q27010323-D8610A6D-9946-4909-AE4D-79102C8724E0Q28280571-C0EE237B-8A99-4727-9DF7-75FC89E609ECQ33376440-C9CFDA19-97A0-4C11-ABDE-7D0AAADE40F7Q33377834-8CC048FD-70AF-47A1-AD63-575322A84313Q33408261-89D0D41D-344B-4AB8-9413-F0D2272B68F4Q33411962-AD3BC5DB-64BA-40EF-A6F8-FFA92CBAD5B6Q33418868-9760971C-5C39-4C9A-A99A-4804E29E7325Q33431220-27FFD01E-C18D-4D15-A9FD-C774C783BE32Q33578564-FCCCFF50-6F9E-492B-B905-E6009CCFF22DQ34541463-5B45A1D4-7D8F-46C8-8202-87EDA3CAFBB4Q34660738-5F7C81B8-3750-43AB-A150-5270836B8C34Q35070414-43798776-26C9-46DD-86DD-6AB63E5C5E49Q35076184-17FCBECE-C046-4BB1-98D7-F094BE75844AQ35180823-5197B8F7-C535-4A75-B7C2-5744F1B57127Q35554515-70013278-F18A-4439-9406-0CCD0F16CAC4Q35771672-95403AF5-0966-40E8-8C7E-7ECA435E7D71Q35823355-CF79620A-996A-45E2-8799-0DEEA64149E6Q35987747-51B83023-829A-4A0A-9989-0E00D2B3A706Q36192053-9647961E-8C42-4211-B4FC-FFB6935EED3AQ36636656-4277A46D-5162-47DB-ADA1-4609EA76E20CQ36689661-6F412418-CF2E-41AF-8A51-4F99B1032AE1Q36859124-407C6935-C4F3-4605-AC2A-17EBCE6ACDDAQ36947812-073D94C1-CE16-4011-A973-F41BCA5F98ECQ37028356-EA5BC075-7412-4767-ADC3-CD564884F09EQ37038897-C9037F67-C75E-4962-BD83-229FAA240BDDQ37277682-332B3514-EAAF-4A29-805B-6B64F36DF7FBQ37283592-4D0109A5-8706-4362-A14B-26172705C514Q37284023-E72DFB0E-DBC1-4EE0-AF0D-089C34925E21Q37312772-E368B827-8455-45EE-B122-BC12117BF853Q37763156-8D1C2493-F3AC-46E5-9C0E-FE8C1BC6ED5CQ37821892-3E439BCD-09D9-4198-B08B-B564245350C0Q37888549-3EB7FB1C-7319-4A93-912E-2BDE63E36E97Q38155201-BC927D7D-3758-4F0E-B179-1907F6610556Q38181169-83EE767A-42D1-4139-BF8D-09AE9287C4D1Q38612831-9EF358A8-3D67-420E-844A-78A284AAF223Q38647100-886E913E-9886-4206-B38F-89E8EF454530Q38701535-6CBBD47B-657F-491A-BB97-B2A7A0BA3AF1Q38711504-E3EAE2D4-8684-497E-9FA6-C5B1C531B62FQ38777610-494879A1-E45E-481F-BFFA-498F0DD6D4C9Q38798645-5096D7B8-87E6-4777-9137-D9BE7514C1C5
P2860
Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy.
description
2001 nî lūn-bûn
@nan
2001 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Chemotherapy with an every-2-w ...... prior cisplatin-based therapy.
@ast
Chemotherapy with an every-2-w ...... prior cisplatin-based therapy.
@en
type
label
Chemotherapy with an every-2-w ...... prior cisplatin-based therapy.
@ast
Chemotherapy with an every-2-w ...... prior cisplatin-based therapy.
@en
prefLabel
Chemotherapy with an every-2-w ...... prior cisplatin-based therapy.
@ast
Chemotherapy with an every-2-w ...... prior cisplatin-based therapy.
@en
P2093
P2860
P1433
P1476
Chemotherapy with an every-2-w ...... prior cisplatin-based therapy
@en
P2093
C N Sternberg
G Pizzocaro
S Schnetzer
P2860
P304
P356
10.1002/1097-0142(20011215)92:12<2993::AID-CNCR10108>3.0.CO;2-2
P407
P577
2001-12-01T00:00:00Z